MRKMerck & Co.

$153.16

$75.8352 weeks$156.44

Price

$153.16+99%1Y

1M+17%1Y+99%

Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.

Smart Score

Above average

8/10

Value45

Quality91

Momentum63

Growth45

Strongest Quality, weakest Growth · ranked vs Healthcare peers. The five questions below judge the company on its own terms.

What they do

Merck & Co., Inc. (Merck or the Company) is a global health care company that delivers innovative health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company’s operations are principally managed on a product basis and include two operating segments, Pharmaceutical and Animal Health, both of which are reportable segments. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

In the company’s own words · 10-K filed Feb 24, 2026 · SEC EDGAR

P/E (TTM)121.6

Market Cap$281.24B

1Y Return+99%

5Y Return+133%

Business segments

Q2 2026 · $9.46B

The company’s own SEC segment disclosure.

Keytruda$4.61B49%
Gardasil Gardasil9$542.0M6%
Winrevair$522.0M6%
Bridion$460.0M5%
Pro Quad MMRII Varivax$438.0M5%
Keytruda Qlex$395.0M4%
Other (23)$2.50B26%

Merck & Co. (MRK) reported revenue of $16.6B in Q2 2026 (quarter ended June 30, 2026), up 5.1% from the same quarter a year earlier. That came with a gross margin of 74% and net loss of $1.33B. For the full year FY2025, revenue was $65.0B (+1.3% year on year) and net income $18.3B. Its largest product in 2026-Q2 was Keytruda at $4.61B, 49% of the disclosed total, just ahead of Gardasil Gardasil9 at 5.7%.

Raw charts

9 series · TTM

As reported to the SEC, without any scoring.

Drug Manufacturers - General

Ranks #11 of 16 by Smart Score